2020 AACR-AstraZeneca Immuno-Oncology Fellow, Maria Casanova-Acebes, PhD, now current head of the Cancer Immunity Group at the Spanish National Cancer Research Centre (CNIO), reported in Nature their findings on how tissue-resident macrophages may influence lung cancer development.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) has been primarily studied in the context of autoimmune diseases. 2019 AACR-InCyte Immuno-oncology Fellow Won Jin Ho, MD, showed how PTPN22 inhibition retards tumor growth in a T-cell- and macrophage-dependent manner.
More than half of melanomas contain extra copies of the sirtuin 5 gene. Two AACR-Bayer Innovation and Discovery grant recipients and an AACR NextGen Grant recipient, along with their colleagues, demonstrated that sirtuin 5 is required for melanoma cell proliferation and survival.
It has long been suggested that consumption of red meat increases the risk of colon cancer. Scientists have now demonstrated a possible mechanistic link between the two in human tumors
A team of investigators led by 2015 KureIt-AACR Grantee Dr. Eliezer Van Allen and Dr. Toni Choueiri probed the changes in the tumor and immune system in advanced renal cell carcinoma patients who received immune check point blockade (ICB).
For a second year in a row, the Global Scholar-in-Training Award (GSITA) program will welcome early-career researchers from around the world to a virtual American Association for Cancer Research Annual Meeting. In an ordinary year, the GSITA program provides...
2018 AACR-AstraZeneca Lung Cancer Fellow Sushil Kumar demonstrated how inhibition of an epigenetic regulator, arginine methyltransferase CARM1, resulted not only in enhanced anti-tumor activity of T cells but also increased susceptibility of tumor cells to T cell-mediated killing.
The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.
Researchers have been trying to get a better understanding of the biodistribution and durability of the CAR T response once inside the body. Two recent publications in Cancer Research and Clinical Cancer Research have reported on two different kinds of PET imaging techniques to monitor the CAR T cells inside the body.
Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...